Cargando…

Correction: Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function

Detalles Bibliográficos
Autores principales:	Allen, Paul, Hird, Emily J., Orlov, Natasza, Modinos, Gemma, Bossong, Matthijs, Antoniades, Mathilde, Sampson, Carly, Azis, Matilda, Howes, Oliver, Stone, James, Perez, Jesus, Broome, Matthew, Grace, Anthony A., McGuire, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632970/ https://www.ncbi.nlm.nih.gov/pubmed/34848677 http://dx.doi.org/10.1038/s41398-021-01731-x

Ejemplares similares

Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function
por: Allen, Paul, et al.
Publicado: (2021)

M163. GLUTAMATE METABOLITES ARE ASSOCIATED WITH ALTERED HIPPOCAMPAL ACTIVATION BUT NOT HIPPOCAMPAL-STRIATAL CONNECTIVITY IN SUBJECTS WITH A CLINICAL HIGH RISK FOR PSYCHOSIS
por: Hird, Emily, et al.
Publicado: (2020)

Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study
por: Howes, Oliver D., et al.
Publicado: (2019)

Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes
por: Modinos, Gemma, et al.
Publicado: (2021)

Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis
por: Modinos, Gemma, et al.
Publicado: (2018)

Integrated metastate functional connectivity networks predict change in symptom severity in clinical high risk for psychosis
por: Gifford, George, et al.
Publicado: (2020)

Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms
por: Modinos, Gemma, et al.
Publicado: (2017)

The Relationship Between Grey Matter Volume and Clinical and Functional Outcomes in People at Clinical High Risk for Psychosis
por: Tognin, Stefania, et al.
Publicado: (2022)

Basic Self-Disturbances Related to Reduced Anterior Cingulate Volume in Subjects at Ultra-High Risk for Psychosis
por: Bonoldi, Ilaria, et al.
Publicado: (2019)

Hippocampal circuit dysfunction in psychosis
por: Knight, Samuel, et al.
Publicado: (2022)

Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis
por: Davies, Cathy, et al.
Publicado: (2019)

Correction: Hippocampal circuit dysfunction in psychosis
por: Knight, Samuel, et al.
Publicado: (2022)

17.3 EFFECT OF CANNABIDIOL ON SYMPTOMS, DISTRESS AND NEUROPHYSIOLOGICAL ABNORMALITIES IN CLINICAL HIGH-RISK FOR PSYCHOSIS PATIENTS: A PLACEBO-CONTROLLED STUDY
por: Bhattacharyya, Sagnik, et al.
Publicado: (2018)

Speech Illusions in People at Clinical High Risk for Psychosis Linked to Clinical Outcome
por: Hird, Emily J, et al.
Publicado: (2022)

Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis
por: Modinos, Gemma, et al.
Publicado: (2019)

Human Striatal Response to Reward Anticipation Linked to Hippocampal Glutamate Levels
por: Bossong, Matthijs G, et al.
Publicado: (2018)

O3.5. TESTING THE DOPAMINE HYPOTHESIS OF PSYCHOSIS USING POSITRON EMISSION TOMOGRAPHIC IMAGING IN FIRST EPISODE BIPOLAR AFFECTIVE DISORDER AND SCHIZOPHRENIA
por: Jauhar, Sameer, et al.
Publicado: (2018)

Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis
por: Wilson, Robin, et al.
Publicado: (2019)

Corticolimbic dysfunction during facial and prosodic emotional recognition in first-episode psychosis patients and individuals at ultra-high risk
por: Tseng, Huai-Hsuan, et al.
Publicado: (2016)

S150. EMOTIONAL BEHAVIOUR IN HIGH-RISK AND FIRST-EPISODE PSYCHOSIS
por: Falkenberg, Irina, et al.
Publicado: (2020)

Effects of Benzodiazepine Exposure on Real-World Clinical Outcomes in Individuals at Clinical High-Risk for Psychosis
por: Livingston, Nicholas R., et al.
Publicado: (2023)

Pattern classification of brain activation during emotional processing in subclinical depression: psychosis proneness as potential confounding factor
por: Modinos, Gemma, et al.
Publicado: (2013)

Acceptability of cannabidiol in patients with psychosis
por: Chesney, Edward, et al.
Publicado: (2022)

Verbal memory performance predicts remission and functional outcome in people at clinical high-risk for psychosis
por: Hedges, Emily P., et al.
Publicado: (2021)

T145. EFFECTS OF CANNABIDIOL ON EMOTION PROCESSING IN PSYCHOSIS RISK: AN FMRI INVESTIGATION
por: Davies, Cathy, et al.
Publicado: (2020)

Parsing neurobiological heterogeneity of the clinical high-risk state for psychosis: A pseudo-continuous arterial spin labelling study
por: Oliver, Dominic, et al.
Publicado: (2023)

A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis
por: Davies, Cathy, et al.
Publicado: (2020)

Verbal learning and hippocampal dysfunction in schizophrenia: A meta-analysis
por: Antoniades, Mathilde, et al.
Publicado: (2018)

Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis
por: Appiah-Kusi, E., et al.
Publicado: (2020)

The Placebo Effect in Psychosis: Why It Matters and How to Measure It
por: Hird, Emily J., et al.
Publicado: (2023)

Longitudinal alterations in motivational salience processing in ultra-high-risk subjects for psychosis
por: Schmidt, A., et al.
Publicado: (2017)

Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report
por: Davies, Cathy, et al.
Publicado: (2021)

Structural Brain Volumes of Individuals at Clinical High Risk for Psychosis: A Meta-analysis
por: Vissink, Conrad E., et al.
Publicado: (2021)

Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies—PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice
por: Tognin, Stefania, et al.
Publicado: (2020)

Functional brain networks before the onset of psychosis: A prospective fMRI study with graph theoretical analysis()()
por: Lord, Louis-David, et al.
Publicado: (2012)

M154. INTRA- AND INTER-SCANNER RELIABILITY OF GRAY MATTER VOLUME AND CORTICAL THICKNESS ESTIMATES: IMPLICATIONS FOR MULTICENTRE IMAGING STUDIES IN PSYCHOSIS
por: Hedges, Emily, et al.
Publicado: (2020)

Neural correlates of emotional processing in psychosis risk and onset – A systematic review and meta-analysis of fMRI studies
por: Lukow, P.B., et al.
Publicado: (2021)

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
por: Batalla, Albert, et al.
Publicado: (2019)

Factors Moderating the Association between Cannabis Use and Psychosis Risk: A Systematic Review
por: van der Steur, Sanne J., et al.
Publicado: (2020)

Altered activation and connectivity in a hippocampal–basal ganglia–midbrain circuit during salience processing in subjects at ultra high risk for psychosis
por: Winton-Brown, T, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a74qf2s4c7pg2b9kk7bh95dsc5